Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to ...

A 14-year study tracking NfL levels in people with the HD gene shows this tiny protein can signal disease progression many ...

Celltrion Inc., a major South Korean biopharmaceutical firm, said Thursday it has launched its biosimilar product for Stelara ...

According to the University of California San Francisco, Huntington’s disease affects one in every 10,000 to 20,000 people in ...

Multiple system atrophy (MSA) is not exactly a household word – a situation that Alterity Therapeutics is seeking to change.

The voucher could save an average of one year of U.S. Food and Drug Administration (FDA) review and be sold by the developer to the manufacturer of a blockbuster drug. In a well-functioning market ...

It is estimated up to 1600 Australians are living with Cushing’s Disease, with about 41 new ... best quality care, cheaper medications, and research into cures and better treatments.” ...

But you’re not. So many women have been right where you are—and you’ve got a way forward too. Whether it’s drugs, alcohol, or prescription medications, recovery is possible, and you deserve the chance ...

Huntington’s disease was long thought to be caused by the slow buildup of a toxic protein, but new research has revealed that it’s actually driven by the expansion of a gene that, at a certain ...

ClearPoint's Q4 updates: neurosurgery growth, expanding services, controlled cash burn and high-potential partner programs driving future prospects. See more here.

Feb 27 (Reuters) - (This Feb. 25 Health Rounds newsletter excerpt has been corrected to indicate in the headline and the first item of the story that Sanofi is no longer involved in the drug's ...